Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Tom Frohlich | $621,970 | $0 | $0 | $8,779,876 | $397,913 | $0 | $0 | $9,799,759 |
| Chief Executive Officer, President and Director | ||||||||
| Andrew King | 507,301 | 0 | 0 | 3,775,903 | 258,600 | 0 | 0 | 4,541,804 |
| President, Research and Development | ||||||||
| Bradford Dahms | 233,013 | 0 | 0 | 3,781,940 | 113,600 | 0 | 3,438 | 4,131,991 |
| Chief Financial Officer | ||||||||
| Timothy Noyes | 213,767 | 0 | 0 | 0 | 0 | 0 | 1,600,716 | 1,814,483 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Tom Frohlich | $9,799,759 | $1,364,396 | — | +8,435,363 |
| Andrew King | 4,541,804 | 751,605 | — | +3,790,199 |
| Bradford Dahms | 4,131,991 | — | — | — |
| Timothy Noyes | 1,814,483 | 3,391,536 | — | −1,577,053 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew King | RSU | 229,907 | — | $3,547,465 |
| Andrew King | RSU | 8,625 | — | 133,084 |
| Tom Frohlich | Option | 817,643 | 6.03 | — |
| Tom Frohlich | Option | 779,934 | 6.03 | — |
| Tom Frohlich | Option | 659,550 | 0.96 | — |
| Andrew King | Option | 184,147 | 6.03 | — |
| Andrew King | Option | 552,709 | 6.03 | — |
| Andrew King | Option | 123,600 | 1.46 | — |
| Bradford Dahms | Option | 526,000 | 9 | — |
The company's compensation program is designed to align the interests of executive officers and stockholders by making a significant portion of compensation 'at risk' based on performance, including short-term cash incentives and long-term equity incentives. The program is weighted toward long-term incentive compensation to discourage short-term risk taking and utilizes multi-year vesting requirements consistent with market practice and retention objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Eric Dobmeier, J.DIndependent · Audit · Nominating and Corporate Governance | $55,688 | — | $171,247 | — | $0 | $226,935 |
| Erin LavelleIndependent · Audit (Chair) · Compensation | 41,175 | — | 171,247 | — | 0 | 212,422 |
| Lawrence Klein, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) | 38,812 | — | 171,247 | — | 0 | 210,059 |
| Lawrence KleinIndependent | 38,812 | — | 171,247 | — | 0 | 210,059 |
| Tomas KiselakIndependent · Compensation (Chair) | 35,100 | — | 171,247 | — | 0 | 206,347 |
| Chris CainIndependent | 34,425 | — | 171,247 | — | 0 | 205,672 |
| Christopher Cain, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 34,425 | — | 171,247 | — | 0 | 205,672 |
| Mark IwickiIndependent · Departed during FY | 26,250 | — | 0 | — | 0 | 26,250 |
| Allison DorvalIndependent · Departed during FY | 25,000 | — | 0 | — | 0 | 25,000 |
| Habib J. DableIndependent · Departed during FY | 21,250 | — | 0 | — | 0 | 21,250 |
| Joshua Resnick, M.DIndependent · Departed during FY | 19,500 | — | 0 | — | 0 | 19,500 |
| David Grayzel, M.DIndependent · Departed during FY | 10,750 | — | 0 | — | 0 | 10,750 |
| Donald J. SantelIndependent · Departed during FY | 9,750 | — | 0 | — | 0 | 9,750 |
| Tom FrohlichEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $390,937 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $390,937 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Jade Biosciences, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Jade Biosciences, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Janux Therapeutics, Inc. | 2025 | David Campbell | $680,000 | $0 | $12,459,031 | $367,200 | $13,506,231 |
| 2 | Dianthus Therapeutics, Inc. | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | Jade Biosciences, Inc. | 2025 | Tom Frohlich | 621,970 | 0 | 8,779,876 | 397,913 | 9,799,759 |
| 4 | CARGO Therapeutics, Inc. | 2024 | Gina Chapman | 630,800 | 0 | 8,155,520 | 363,800 | 9,300,120 |
| 5 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 6 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 7 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 8 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 9 | Upstream Bio, Inc. | 2025 | E. Rand Sutherland | 650,000 | 0 | 3,300,350 | 341,250 | 4,302,100 |
| 10 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 11 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 12 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 13 | Contineum Therapeutics, Inc. | 2025 | Carmine Stengone | 655,620 | 0 | 2,291,640 | 450,739 | 3,409,448 |
| 14 | Oruka Therapeutics, Inc. | 2025 | Lawrence Klein | 624,000 | 0 | 2,275,390 | 446,160 | 3,356,050 |
| 15 | Kyverna Therapeutics, Inc. | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| — | Alumis Inc. | — | — | — | — | — | — | not in coverage universe |
| — | ACELYRIN, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Apogee Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Third Harmonic Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Zenas BioPharma, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Jade Biosciences, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| ACELYRIN, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Alumis Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Apogee Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Astria Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Aon |
| CARGO Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Contineum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Dianthus Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Janux Therapeutics, Inc. | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon plc |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| Oruka Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards LLC |
| Pliant Therapeutics, Inc. | 50% | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| Prime Medicine, Inc. | 120% | Options 100 | not disclosed | Alpine Rewards |
| Spyre Therapeutics, Inc. | 130% | Options 100 | not disclosed | Alpine Rewards |
| Third Harmonic Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Upstream Bio, Inc. | 52.5% | Options 100 | not disclosed | Alpine Rewards |
| Zenas BioPharma, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Tom Frohlich | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 9,799,759. Filing ↗machine: r2 · c23 · span 401361–401370 |
| 2 | Section 01, Andrew King | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,541,804. Filing ↗machine: r4 · c23 · span 406661–406670 |
| 3 | Section 01, Bradford Dahms | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,131,991. Filing ↗machine: r6 · c23 · span 411876–411885 |
| 4 | Section 01, Timothy Noyes | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 1,814,483. Filing ↗machine: r8 · c23 · span 416137–416146 |
| 5 | Section 08, Eric Dobmeier, J.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 226,935. Filing ↗ |
| 6 | Section 08, Erin Lavelle | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 212,422. Filing ↗ |
| 7 | Section 08, Lawrence Klein, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 210,059. Filing ↗ |
| 8 | Section 08, Lawrence Klein | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 210,059. Filing ↗ |
| 9 | Section 08, Tomas Kiselak | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 206,347. Filing ↗ |
| 10 | Section 08, Chris Cain | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 205,672. Filing ↗ |
| 11 | Section 08, Christopher Cain, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 205,672. Filing ↗ |
| 12 | Section 08, Mark Iwicki | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 26,250. Filing ↗ |
| 13 | Section 08, Allison Dorval | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 25,000. Filing ↗ |
| 14 | Section 08, Habib J. Dable | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 21,250. Filing ↗ |
| 15 | Section 08, Joshua Resnick, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 19,500. Filing ↗ |
| 16 | Section 08, David Grayzel, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 10,750. Filing ↗ |
| 17 | Section 08, Donald J. Santel | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 9,750. Filing ↗ |
| 18 | Section 08, Tom Frohlich | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 20 | Section 09b board cost (computed) | Computed | — | computed | Cash 390,937 + equity 0 + all other 0 = 390,937, summed across the director compensation table rows.machine: formula: Σ = 390,937 |
| 21 | Janux Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics, Inc.'s own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 22 | Dianthus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001690585-26-000012 | CEO total compensation as printed in Dianthus Therapeutics, Inc.'s own proxy. As printed: 10,614,702. Filing ↗machine: r2 · c25 · span 382326–382336 |
| 23 | Jade Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187059 | CEO total compensation as printed in Jade Biosciences, Inc.'s own proxy. As printed: 9,799,759. Filing ↗machine: r2 · c23 · span 401361–401370 |
| 24 | CARGO Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001193125-25-103786 | CEO total compensation as printed in CARGO Therapeutics, Inc.'s own proxy. As printed: 9,300,120. Filing ↗machine: r2 · c31 · span 289578–289587 |
| 25 | Kymera Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 26 | Spyre Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001636282-26-000039 | CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. Filing ↗machine: r2 · c48 · span 393018–393027 |
| 27 | Astria Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-28 | 0001104659-25-040180 | CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460 |
| 28 | Pliant Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 29 | Upstream Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-158966 | CEO total compensation as printed in Upstream Bio, Inc.'s own proxy. As printed: 4,302,100. Filing ↗machine: r2 · c24 · span 433625–433634 |
| 30 | Lyell Immunopharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016686 | CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172 |
| 31 | Prime Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 32 | Entrada Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001689375-26-000021 | CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
| 33 | Contineum Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028881 | CEO total compensation as printed in Contineum Therapeutics, Inc.'s own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |
| 34 | Oruka Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045159 | CEO total compensation as printed in Oruka Therapeutics, Inc.'s own proxy. As printed: 3,356,050. Filing ↗machine: r1 · c12 · span 534154–534163 |
| 35 | Kyverna Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001193125-26-152835 | CEO total compensation as printed in Kyverna Therapeutics, Inc.'s own proxy. As printed: 1,814,980. Filing ↗machine: r2 · c26 · span 547940–547949 |
| 36 | Section 10a, Janux Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 37 | Section 10a, Spyre Therapeutics, Inc. reciprocity | DEF 14A | — | 0001636282-26-000039 | Spyre Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 38 | Section 10a, Astria Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040180 | Astria Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 39 | Section 10a, Kymera Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 40 | Section 10a, Contineum Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028881 | Contineum Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 41 | Section 10a, Dianthus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001690585-26-000012 | Dianthus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 42 | Section 10a, Oruka Therapeutics, Inc. reciprocity | DEF 14A | — | 0001213900-26-045159 | Oruka Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 43 | Section 10a, Pliant Therapeutics, Inc. reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |